Drug Price Trends for NDC 59762-0407
✉ Email this page to a colleague
Average Pharmacy Cost for 59762-0407
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 24.74633 | EACH | 2025-12-17 |
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 24.16283 | EACH | 2025-11-19 |
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 24.13533 | EACH | 2025-10-22 |
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 23.88758 | EACH | 2025-09-17 |
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 24.26817 | EACH | 2025-08-20 |
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 24.54983 | EACH | 2025-07-23 |
| RISEDRONATE SOD DR 35 MG TAB | 59762-0407-04 | 25.24379 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59762-0407
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59762-0407
Introduction
NDC 59762-0407 pertains to a specific pharmaceutical product registered in the U.S. National Drug Code (NDC) directory. Analyzing its market landscape and future pricing involves detailed assessment of therapeutic indications, manufacturer landscape, regulatory environment, competitive dynamics, and pricing trends. This report synthesizes relevant data and projections to inform stakeholders on current valuation and future opportunities.
Product Overview and Therapeutic Indication
While specific details for NDC 59762-0407 are proprietary, NDC codes often correspond to a unique drug, its formulation, and packaging. Typically, such codes cover branded or generic medications. The absence of explicit product details necessitates focusing on the broader therapeutic class likely associated with this NDC segment.
Assuming it belongs to a niche therapeutic class—such as biologics, proprietary small molecules, or specialty drugs—its market valuation hinges on the drug’s indication, such as oncology, autoimmune disorders, or rare diseases. These categories generally command higher prices due to limited competition and high unmet needs [1].
Key Insight:
The absence of publicly disclosed specifics restricts precise modeling. Nonetheless, understanding the general market for targeted therapies or biologics helps shape projections.
Current Market Landscape
Market Size & Demand Dynamics
The U.S. pharmaceutical market for specialty drugs, particularly in niche therapeutic areas, is expanding rapidly. The global pharmaceutical market was valued at approximately $1.27 trillion in 2021, with specialty drugs accounting for over 50% of sales—expected to grow annually by 8-10% [2].
Within this scope, drugs addressing rare diseases or complex conditions benefit from incentives like Orphan Drug Status, leading to exclusivity and higher pricing power. Drugs of this class typically see annual sales ranging from $100 million to over a billion dollars, depending on approval status, efficacy, and market penetration.
Competitive Environment
The competitive landscape features several key factors:
- Existing approved therapies and biosimilars if applicable.
- Entry barriers such as regulatory approval timelines.
- Patent life and exclusivity periods.
- Manufacturer market share strategies—price positioning, reimbursement negotiations, and formulary placements.
Current market data indicates that first-in-class drugs or those with significant clinical advantages often secure premium pricing and rapid uptake.
Regulatory & Reimbursement Factors
Regulatory approvals from the FDA are critical. New indications or biosimilar entrants can affect market sustainability.
Reimbursement policy analysis shows payer willingness to cover high-cost specialty drugs depends on clinical value demonstration, cost-effectiveness, and real-world outcomes. The increasing emphasis on value-based care influences pricing strategies [3].
Price Trends and Projections
Historical Pricing Trends
Historically, specialty drugs have experienced substantial price inflation. From 2010 onwards, many drugs have seen double-digit annual increases, driven by R&D recoupment, manufacturing costs, and market exclusivity periods.
- Biologic and specialty drug prices often range from $20,000 to over $100,000 annually per patient.
- The average wholesale price (AWP) for niche therapies has increased by approximately 5-8% annually in recent years.
Example:
In 2019, the median wholesale acquisition cost (WAC) for oncology biologics was around $100,000 per year [4].
Projected Trends (2023-2028)
Based on current trajectories, the following projections are reasonable:
- Price stabilization at high levels: Expected to plateau around the current WAC, with minor annual adjustments (~3-4%) aligned with inflation and cost-of-living increases.
- Impact of biosimilars and generics: Introduction of biosimilars can reduce prices by 15-20%, but premium pricing persists where the original demonstrates significant clinical benefit.
- Value-based reimbursement schemes: May constrain rapid price increases, promoting negotiated discounts in managed care settings.
- Regulatory pressures: Increased scrutiny over R&D costs and drug pricing could induce downward pressure, particularly if government intervention occurs.
- Inflation-adjusted estimates:
- If the current average price is ~$50,000 (hypothetical for illustration), prices may remain within $48,000–$55,000 over the next five years, considering market factors.
Implications for Stakeholders
- Pharmaceutical manufacturers: Maintaining exclusivity and demonstrating superior efficacy will support premium pricing.
- Payers and providers: Continuous negotiation and formulary placements are vital to managing costs.
- Investors: Long-term value hinges on market penetration and patent life maintenance.
Market Opportunities and Risks
Opportunities:
More… ↓
